Introduction
Leading pharmaceutical company received European authorization for its Rotigotine transdermal patch, indicated for Parkinson’s and Restless Legs Syndrome, marking first transdermal approval from its Bengaluru facility for European markets.
Also Read: Astra Microwave gains on winning ₹171.38 Cr order for IMD radar
Share price movement of Shilpa Medicare
On December 12, 2025, Shilpa Medicare Ltd opened at ₹329.05, up 0.40% from its previous close of ₹327.70. The stock reached a high of ₹339.40 (3.35%) and a low of ₹322.50. By 3:40 PM, it traded at ₹328.50, a 0.24% increase, with a market cap of ₹6,424.86 crore.
Shilpa Medicare Gains European Patch Approval
Shilpa Medicare Limited received initial authorization from Europe for its Rotigotine transdermal patch, covering 1, 2, 3, 4, 6, and 8 mg/24 h strengths. The patch treats Parkinson’s and Restless Legs Syndrome.
The product is a generic, pharmaceutical, and bioequivalent version of Neupro®. The total European market for Rotigotine is estimated at approximately USD 222 million. The company has partnered with a commercialization partner for launch in FY27.
The approval comes from Shilpa Medicare’s Unit VI facility in Dobbaspet, Bengaluru. This marks the company’s first transdermal patch dosage authorization in Europe, manufactured, packaged, labelled, and tested at the facility.
Stock performance of Shilpa Medicare for Period of 1 week, 6 months, and 1 year
Shilpa Medicare Ltd delivered a -1.25% return over the past week, it declined by 33.6% in the past six months. The stock fell 20.1% over the past year.
Also Read: Tembo Global Industries secures ₹700 crore pipeline for large industrial projects
Shareholding pattern of Shilpa Medicare
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 44.20% | 44.20% | 44% |
| FII | 10.90% | 11.20% | 11% |
| DII | 7.70% | 7.50% | 7.60% |
| Public | 37.20% | 37.10% | 37.30% |
About Shilpa Medicare
Shilpa Medicare Limited (NSE: SHILPAMED) is a leading Indian pharmaceutical company developing, manufacturing, and marketing APIs, formulations, and biologics across oncology, infectious diseases, and specialty segments, serving patients in over 80 countries.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Shilpa Medicare Ltd share price going up today?
A: Shilpa Medicare Ltd share price rose after receiving initial European authorization for its Rotigotine transdermal patch for Parkinson’s and Restless Legs Syndrome.
Q: What does Shilpa Medicare Ltd specialize in?
A: Shilpa Medicare Ltd specializes in development, manufacture, and marketing of APIs, formulations, and biologics across oncology, infectious diseases, and specialty segments.
Q: What is the market capitalization of Shilpa Medicare Ltd?
A: The market capitalization of Shilpa Medicare Ltd is ₹6,424.86 crore as of December 12, 2025.
